Su Hung-Chieh, Chang Yu-Chang, Chen Chih-Hao, Cheng Meng-Yu, Hsih Wen-Hsin, Chen Yi-Jhen, Chou Chia-Huei, Lin Yu-Chao, Hsiao Chiung-Tzu, Shih Hong-Mo, Ho Mao-Wang, Hsueh Po-Ren
Division of Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan.
Department of Laboratory Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan.
J Microbiol Immunol Infect. 2024 Dec;57(6):868-878. doi: 10.1016/j.jmii.2024.08.003. Epub 2024 Aug 12.
The emergence of SARS-CoV-2 in late 2019 sparked the global COVID-19 pandemic, leading to varied vaccine policies worldwide. The evolving patterns of respiratory pathogens, aside from SARS-CoV-2, during the pandemic have had a significant impact on the development of vaccine strategies.
This study explores the landscape of respiratory pathogens, encompassing SARS-CoV-2, respiratory syncytial virus (RSV), and influenza viruses, through a retrospective analysis of data obtained from the BioFire Respiratory Panel 2.1 (RP 2.1) at China Medical University Hospital (Taichung, Taiwan) spanning from January 2020 to November 2023.
Among the 7950 respiratory samples studied, pediatric cases exhibited higher positivity (64.9%, 2488/3835) and mixed detection rates (43.8%, 1090/2488) than adults. Annual mixed detection rates increased (27.9-48%). Prevalence analysis revealed diverse patterns across age groups, with higher rates in pediatrics. Notably, human rhinovirus/enterovirus predominated (48.1%). Mixed detection illustrated viral co-detections, notably with parainfluenza viruses and adenovirus. Government policies and pandemic dynamics influenced infection patterns, with RSV resurgence after May 2022. Age-specific RSV detection demonstrated a shift, influencing vaccine considerations. Amid global vaccine initiatives, RSV's increasing trend in adults warrants attention.
This comprehensive analysis emphasizes the importance of multiplex PCR testing in shaping targeted vaccination strategies during evolving respiratory pathogen landscapes.
2019年末严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的出现引发了全球新冠疫情，导致全球疫苗政策各异。疫情期间，除SARS-CoV-2外，呼吸道病原体的演变模式对疫苗策略的制定产生了重大影响。
本研究通过回顾性分析中国医科大学附设医院（中国台湾台中）2020年1月至2023年11月期间从BioFire呼吸病原体检测板2.1（RP 2.1）获得的数据，探讨包括SARS-CoV-2、呼吸道合胞病毒（RSV）和流感病毒在内的呼吸道病原体情况。
在研究的7950份呼吸道样本中，儿科病例的阳性率（64.9%，2488/3835）和混合检测率（43.8%，1090/2488）高于成人。年度混合检测率有所上升（27.9%-48%）。患病率分析显示各年龄组模式不同，儿科患病率较高。值得注意的是，人鼻病毒/肠道病毒占主导（48.1%）。混合检测显示了病毒共检测情况，尤其是与副流感病毒和腺病毒。政府政策和疫情动态影响感染模式，2022年5月后RSV卷土重来。特定年龄的RSV检测显示出变化，影响了疫苗考量。在全球疫苗倡议背景下，RSV在成人中的上升趋势值得关注。
这项综合分析强调了多重聚合酶链反应检测在不断演变的呼吸道病原体环境中制定针对性疫苗策略方面的重要性。
